Purpose: To analyze the modern possibilities of primary and secondary prophylaxis in gynecological cancers and their place in the medical practice in our country.
Materials And Methods: The data of the Bulgarian National Cancer Registry and the relevant world literature served as a source for review and analysis of different primary and secondary prevention measures for gynecological malignancies.
Results: For 2003 high levels of incidence and mortality were established: standardized yearly incidence of cervical cancer 19.3 x 10(5), of endometrial cancer 15.9 x 10(5) and of ovarian cancer 11.9 x 10(5). Most stressing is the tendency of their constant increase during the last 15 years. For primary prophylaxis, optimal body weight, proper food intake, indicated hormone replacement therapy, prophylactic oophorectomy and introduction of prophylactic vaccines are recommended. Secondary prophylaxis of cervical cancer is carried out through cytological screening and colposcopy with targeted biopsy, of endometrial cancer with endometrial biopsy, of ovarian cancer by means of gynecological exam, ultrasound and tumor marker CA 125.
Conclusion: Analysis of modern primary and secondary prophylaxis of gynecological cancers shows that in our country the key point of medical practice is the introduction of organized screening programs, duly implementation of new technologies and quality control of this work.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of BI 1358894 in Patients With Borderline Personality Disorder: Results of a Phase 2 Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Trial.
J Clin Psychiatry
January 2025
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.
To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD). This was a phase 2, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to oral placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) once daily in a 2.
View Article and Find Full Text PDFDyslipidemia: recommendations for diagnosis and treatment at the first level of medical contact.
Gac Med Mex
January 2025
Clínica de Hipertensión y Riesgo Cardiovascular, ISSSTESon, Hermosillo, Sonora. México.
Cardiovascular disease is the main cause of mortality in Mexico as well as the rest of the world, with dyslipidemia being one of the main risk factors. Despite the importance of its epidemiological impact, there is still -among primary care physicians- a lack of knowledge ranging from the basic concepts for diagnosis to the most recent recommendations for treatment. This document consisting of 10 questions is done by experts in this field.
View Article and Find Full Text PDFGeographical and Socioeconomic Disparities in Substance and Opioid Use Disorders Among Inflammatory Bowel Disease Hospitalizations in the United States From the National Inpatient Sample.
J Clin Psychiatry
January 2025
Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
We compared substance use disorder (SUD) prevalence among adult inflammatory bowel disease (IBD) hospitalizations with non-IBD controls from the 2016-2018 National Inpatient Sample, assessing correlations with demographics, socioeconomic status, geographic regions, depression, and anxiety. The primary aim focused on SUD, defined as substance abuse or dependence (: F10-F19) excluding unspecified use or remission, among hospitalizations documenting IBD (Crohn's disease or ulcerative colitis; : K50-51) as one admitting diagnosis (IBD-D). The prevalence of SUD among hospitalizations with and without IBD was compared.
View Article and Find Full Text PDFOlanzapine/Samidorphan Effects on Weight Gain: An Individual Patient Data Meta-Analysis of Phase 2 and 3 Randomized Double-Blind Studies.
J Clin Psychiatry
January 2025
Division of Pharmacotherapy and Translational Science, College of Pharmacy, University of Texas at Austin, San Antonio, Texas.
To evaluate weight change with a combination of olanzapine and samidorphan (OLZ/SAM) versus olanzapine by pooling data across clinical studies. This study was an individual patient data (IPD) meta-analysis of clinical trial data. EMBASE, MEDLINE, and PsycInfo were searched for randomized clinical trials (≥12 weeks) in adults with schizophrenia or bipolar I disorder in which weight change from baseline was the primary or secondary end point.
View Article and Find Full Text PDFPharmacogenetic associations of GATA4 and KCNQ1 with ibrutinib cardiovascular toxicity.
Pharmacogenet Genomics
January 2025
Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan.
Ibrutinib treatment is often complicated by cardiovascular side effects (CVSEs). The objective of this retrospective pharmacogenetic study is to replicate a previously reported association of 'high-risk' patients, who are homozygous carriers of at least two of GATA4 rs804280 AA, KCNQ1 rs163182 GG, and KCNQ1 rs2237895 AA, with increased risk of hypertension or atrial fibrillation, and explore associations for other pharmacogenes (e.g.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!